Targets › TNFRSF8
3 programs from 2 companies in 38 trials: 27 Phase 2, 6 Phase 1, 4 Phase 3, 1 Phase 4; Oncology, Hematology; next expected readout Mar 2027.
Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. (UniProt, P28908)
Open in Phaseline: the race on TNFRSF8, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Takeda | Brentuximab Vedotin Tubulin inhibitor; Tumor necrosis factor receptor superfamily member 8 binding agent | Tubulin, TNFRSF8 | Phase 4 | Hodgkin Lymphoma; Lymphoma; Hodgkin Disease; Ann Arbor Stage III Hodgkin Lymphoma … | Dec 2027 |
| City of Hope Medical Center | Actinium Ac 225-DOTA-Daratumumab Anti-CD38 monoclonal antibody conjugated to actinium-225, delivering targeted alpha radiat | TNFRSF8 | Phase 1 | Recurrent Plasma Cell Myeloma | Mar 2027 |
| City of Hope Medical Center | Indium In 111-DOTA-Daratumumab Anti-CD38 monoclonal antibody conjugated to indium-111, delivering targeted gamma radiatio | TNFRSF8 | Phase 1 | Recurrent Plasma Cell Myeloma | Mar 2027 |
Hodgkin Lymphoma (7) Lymphoma (2) Mycosis Fungoides (2) Ann Arbor Stage I Hodgkin Lymphoma (2) Classical Hodgkin Lymphoma (2) Recurrent Classic Hodgkin Lymphoma (2) Recurrent Plasma Cell Myeloma (2) Hodgkin Disease (1) Ann Arbor Stage III Hodgkin Lymphoma (1) Ann Arbor Stage IIB Hodgkin Lymphoma (1) Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 (1) Ann Arbor Stage IB Hodgkin Lymphoma (1)
antibody (2), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.